All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Susan O’Brien, MD, is Associate Director for Clinical Science at the Chao Family Comprehensive Cancer Center, Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, and Professor of Medicine at University of California Irvine, Irvine, US.
Professor O’Brien is an internationally recognized leader in the research of treatments for both chronic and acute leukemias and an acknowledged expert on several important treatments that are currently used as the standard of care for chronic lymphocytic leukemia. She has been closely involved with clinical research that has led to many key discoveries which have advanced the understanding and treatment of the disease. Prof. O’Brien is involved with multiple professional organizations, such as the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research. She is a Hematology Member of the SWOG Executive Committee. She is also a Section Editor for Cancer and has authored and co-authored over 800 peer-reviewed articles.
Positions of responsibility/awards: